Lipopolysaccharide Binding Protein and Development of Infectious Events in Cirrhotic Patients
Association of Serum Levels of Lipopolysaccharide Binding Protein (LBP) With the Evolution of Pro- and Anti-inflammatory Cytokines, and the Development of Severe Infectious Events in Cirrhotic Patients
  • Phase

    Phase 4
  • Study Type

  • Status

  • Study Participants

The purpose of this study is to determine whether plasma levels of lipopolysaccharide binding protein (LBP) are correlated with PBMN pro- and anti-inflammatory cytokine secretion, as well as with the development of severe infectious events in cirrhotic patients with ascites. As a secondary purpose, the study will evaluate the effect of a prophylactic administration of ciprofloxacin on LBP, cytokines and infections in the same patients.
Study Started
Sep 24
Last Update
Dec 05

Drug Ciprofloxacin

Ciprofloxacin oral, 500 mg capsules, one capsule per day during four weeks.

  • Other names: Ciproflox

Drug Placebo

Placebo capsules, one capsule per day during four weeks.

Active Experimental


Placebo Placebo Comparator



Inclusion Criteria:

No history of spontaneous bacterial peritonitis and/or < 1 g of protein in ascites
No antibiotic use in previous 6 weeks
Absence of infection (documented by clinical history, blood cytology, urinalysis and urine culture, thorax x-ray and paracentesis)
Absence of GI bleeding or encephalopathy
Signature of informed consent

Exclusion Criteria:

Ciprofloxacin contraindication
Autoimmune hepatitis, sclerosing cholangitis or other autoimmune disease
> 13 Child-Pugh points
Inability to attend to regular visits
Current alcohol intake
Terminal disease with < 24 week expected survival
No Results Posted